Tenofovir Alafenamide
Brand name: Vemlidy
Rank #207 of 500 drugs by total cost
$68.7M
Total Cost
44,509
Total Claims
$68.7M
Total Cost
1,226
Prescribers
$1,543
Cost per Claim
2,392
Beneficiaries
46,959
30-Day Fills
$56K
Avg Cost/Provider
36
Avg Claims/Provider
About Tenofovir Alafenamide
Tenofovir Alafenamide (sold as Vemlidy) was prescribed 44,509 times by 1,226 Medicare Part D providers in 2023, costing the program $68.7M. At $1,543 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 204 | Immun Glob G(Igg)-Ifas/Glycine (Panzyga) | $70.1M | 4,693 |
| 205 | Buprenorphine Hcl (Buprenorphine Hcl) | $69.7M | 205,349 |
| 206 | Prednisolone Acetate (Prednisolone Acetate) | $68.8M | 1,486,663 |
| 207 | Tenofovir Alafenamide (Vemlidy) | $68.7M | 44,509 |
| 208 | Abaloparatide (Tymlos) | $68.4M | 24,417 |
| 209 | Treprostinil Diolamine (Orenitram Er) | $68.2M | 5,964 |
| 210 | Esomeprazole Magnesium (Esomeprazole Magnesium) | $66.3M | 964,193 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology